EP1326605A4 - METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS - Google Patents

METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS

Info

Publication number
EP1326605A4
EP1326605A4 EP01935770A EP01935770A EP1326605A4 EP 1326605 A4 EP1326605 A4 EP 1326605A4 EP 01935770 A EP01935770 A EP 01935770A EP 01935770 A EP01935770 A EP 01935770A EP 1326605 A4 EP1326605 A4 EP 1326605A4
Authority
EP
European Patent Office
Prior art keywords
methods
cancer cells
inducing apoptosis
inhibiting proliferation
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01935770A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1326605A1 (en
Inventor
Thomas E Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of EP1326605A1 publication Critical patent/EP1326605A1/en
Publication of EP1326605A4 publication Critical patent/EP1326605A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01935770A 2000-05-09 2001-05-08 METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS Withdrawn EP1326605A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US219344P 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
EP1326605A1 EP1326605A1 (en) 2003-07-16
EP1326605A4 true EP1326605A4 (en) 2004-03-17

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01935770A Withdrawn EP1326605A4 (en) 2000-05-09 2001-05-08 METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS

Country Status (11)

Country Link
EP (1) EP1326605A4 (zh)
JP (1) JP2003532675A (zh)
KR (1) KR20030019372A (zh)
CN (1) CN1237968C (zh)
AU (1) AU2001261832A1 (zh)
BR (1) BR0110473A (zh)
CA (1) CA2408622A1 (zh)
MX (1) MXPA02010974A (zh)
NO (1) NO20025343L (zh)
NZ (1) NZ522387A (zh)
WO (1) WO2001085166A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EA023067B1 (ru) 2012-01-10 2016-04-29 Эли Лилли Энд Компани Соединение, представляющее собой антагонист лейкотриена b
RU2667644C2 (ru) 2013-04-22 2018-09-21 Тотиги Инститьют Оф Клиникал Патолоджи Противоопухолевое средство
BR112016011170B1 (pt) 2013-12-20 2023-01-10 Novartis Ag Derivados de ácido heteroaril butanóico, seus usos, combinação e composição farmacêutica

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0185166A1 *
STEELE V E ET AL: "LIPOXYGENASE INHIBITORS AS POTENTIAL CANCER CHEMOPREVENTIVES", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 8, no. 5, May 1999 (1999-05-01), pages 467 - 483, XP000984604, ISSN: 1055-9965 *

Also Published As

Publication number Publication date
MXPA02010974A (es) 2004-09-06
CN1237968C (zh) 2006-01-25
AU2001261832A1 (en) 2001-11-20
NZ522387A (en) 2003-09-26
NO20025343L (no) 2003-01-09
EP1326605A1 (en) 2003-07-16
KR20030019372A (ko) 2003-03-06
CA2408622A1 (en) 2001-11-15
NO20025343D0 (no) 2002-11-07
JP2003532675A (ja) 2003-11-05
WO2001085166A1 (en) 2001-11-15
CN1429111A (zh) 2003-07-09
BR0110473A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
AU2003284242A8 (en) Methods and compositions for use in treating cancer
AU2002252160A1 (en) Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
MXPA02001866A (es) Cateter de drenaje lumbar.
AU3104102A (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
HK1045299B (zh) 細胞增殖抑制劑
AU2003243373A8 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
AU3731400A (en) Methods and compositions useful in inhibiting apoptosis
EP1587476A4 (en) COMPOSITIONS AND METHODS FOR CANCER THERAPY
AU2003258061A8 (en) Therapeutic inhibitionof protein kinases in cancer cells
EP1581542A4 (en) NEW COMPOSITIONS AND METHODS OF TREATING CANCER
AU5137901A (en) Method to inhibit lipoxygenase and cancer cell proliferation
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2002356898A8 (en) Gene amplification and overexpression in cancer
EP1664739A4 (en) ONLINE TREATMENT AND IRRADIATION SYSTEM
EP1609802A4 (en) TRANSCRIPTIONAL FACTOR INDUCING APOPTOSIS IN A CANCER CELL
EP1501855A4 (en) NEW COMPOSITIONS AND METHODS FOR CANCER
EP1326605A4 (en) METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS
HK1048599A1 (zh) 癌細胞植入抑制劑
GB2389788B (en) Methods for inducing apoptosis and inhibiting proliferation in cancer cells
EP1459756A4 (en) DISTANCE PHOTO MOTOR AND INHIBITORS FOR APOPTOSIS CELLS IN VIVO
EP1636384A4 (en) GENEAVIFICATION AND OVEREXPRESSION IN CANCER
GB9818712D0 (en) In pond multi-skimmer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
EP1583501A4 (en) NEW COMPOSITIONS AND METHOD FOR CARCINOMA
GB2419530B (en) Human prostate cell lines in cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021205

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040130

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/352 B

Ipc: 7A 61K 31/194 B

Ipc: 7A 61K 31/41 A

17Q First examination report despatched

Effective date: 20041007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061031

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057471

Country of ref document: HK